Inventor
Atul Agarwal
Inventor
Hamden, CT, US
Overview
Patents· 50 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations24%
C07DHeterocyclic compounds22%
A61KPreparations for medical, dental or toiletry purposes21%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium15%
C07BGeneral methods of organic chemistry12%
C07KPeptides5%
Y02ATechnologies for adaptation to climate change2%
PatentTitleYear
11,084,800Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders202111,053,253Macrocyclic compounds for treatment of medical disorders202111,001,600Disubstituted compounds for treatment of medical disorders202110,919,884Amide compounds for treatment of immune and inflammatory disorders202110,906,887Amino compounds for treatment of immune and inflammatory disorders202110,822,352Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders202010,807,952Compounds for treatment of immune inflammatory disorders202010,689,409Amino compounds for treatment of complement mediated disorders202010,662,175Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders202010,660,876Amino compounds for treatment of medical disorders202010,550,140Ether compounds for treatment of complement mediated disorders202010,464,956Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders201910,428,094Amide compounds for treatment of complement mediated disorders201910,428,095Compounds for treatment of complement mediated disorders201910,385,097Ether compounds for treatment of medical disorders201910,370,394Carbamate, ester, and ketone compounds for treatment of complement mediated disorders201910,301,336Phosphonate compounds for treatment of complement mediated disorders201910,287,301Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders201910,253,053Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders201910,189,869Amino compounds for treatment of complement mediated disorders201910,138,225Amide compounds for treatment of medical disorders201810,106,563Ether compounds for treatment of complement mediated disorders201810,100,072Phosphonate compounds for treatment of complement mediated disorders201810,092,584Compounds for the treatment of medical disorders201810,087,203Compounds for treatment of complement mediated disorders201810,081,645Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders201810,011,612Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders201810,005,802Amide compounds for treatment of complement mediated disorders201810,000,516Phosphonate compounds for treatment of medical disorders20189,828,396Alkyne compounds for treatment of complement mediated disorders20179,796,741'Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders'20179,758,537'Compounds for treatment of complement mediated disorders'20179,732,104'Ether compounds for treatment of complement mediated disorders'20179,732,103'Carbamate, ester, and ketone compounds for treatment of complement mediated disorders'20179,695,205'Amide compounds for treatment of complement mediated disorders'20179,663,543'Phosphonate compounds for treatment of complement mediated disorders'20179,610,317'4-amino-4-oxobutanoyl peptides as inhibitors of viral replication'20179,598,446'Amino compounds for treatment of complement mediated disorders'20179,233,136'4-amino-4-oxobutanoyl peptides as inhibitors of viral replication'20168,785,378'Macrocyclic peptides as inhibitors of viral replication'20148,697,641'4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication'20148,614,180'4-amino-4-oxobutanoyl peptides as inhibitors of viral replication'20138,435,984'Tertiary amine substituted peptides useful as inhibitors of HCV replication'20137,906,619'4-amino-4-oxobutanoyl peptides as inhibitors of viral replication'20117,812,014'Bicyclic 6-alkylidene-penems as β-lactamase inhibitors'20107,691,842'Tricyclic 6-alkylidene-penems as β-lactamase inhibitors'20107,183,300'Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof'20077,112,582'Bicyclic 6-alkylidene-penems as β-lactamase inhibitors'20067,018,997'Tricyclic 6-alkylidene-penems as β-lactamase inhibitors'20066,489,476'Heteroaromatic compounds containing a phosphonate group that are inhibitors of fructose-1,6-bisphosphatase'2002Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2002Based in San Diego, CA, US· patent location history
2006–2021Based in Hamden, CT, US· patent location history
2007–2014Patents assigned to AGARWAL ATUL (4)· patent assignee history
2011–2021Patents assigned to ACHILLION PHARMACEUTICALS INC (43)· patent assignee history
2013–2014Patents assigned to PHADKE AVINASH (3)· patent assignee history
2013–2014Patents assigned to WANG XIANGZHU (3)· patent assignee history
2013–2014Patents assigned to ZHANG SUOMING (3)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ACHILLION PHARMACEUTICALS INC | 43 | 2011–2021 |
| AGARWAL ATULself | 4 | 2007–2014 |
| PHADKE AVINASH | 3 | 2013–2014 |
| WANG XIANGZHU | 3 | 2013–2014 |
| ZHANG SUOMING | 3 | 2013–2014 |
Locations
| Location | Patents | Span |
|---|---|---|
| Hamden, CT, US | 49 | 2006–2021 |
| San Diego, California, US | 1 | 2002 |